Stock Market News
FDA gives AstraZeneca's Tagrisso the thumbs up for first-line treatment
AstraZeneca announced on Thursday that the US Food and Drug Administration has approved Tagrisso (osimertinib) for the first-line treatment of patients with metastatic non-small cell lung cancer, whose tumours have epidermal growth factor receptor mutations as detected by an FDA-approved test.
The FTSE 100 drugmaker said the approval was based on results from the Phase III FLAURA trial, which were presented at the European Society of Medical Oncology 2017 Congress and published in the New England Journal of Medicine.
"Today's FDA approval of Tagrisso in the first-line setting is an exciting milestone for patients and our company," said Dave Fredrickson, executive vice president, head of the oncology business unit at AstraZeneca.
"Tagrisso delivered unprecedented median progression-free survival data across all pre-specified patient subgroups, including patients with or without CNS metastases, and could prolong the lives of more patients without their tumours growing or spreading."
Dr Suresh S Ramalingam, the principal investigator of the FLAURA trial from the Winship Cancer Institute of Emory University in Atlanta, said the approval of osimertinib in the first-line setting represented a "major advance" in the treatment of patients with epidermal growth factor receptor mutations, and a "significant change" in the treatment paradigm.
"Osimertinib provides robust improvements in progression-free survival with no unexpected safety signals compared to the previous generation of EGFR inhibitors."
AstraZeneca said the FLAURA trial compared Tagrisso to current first-line tyrosine kinase inhibitors - erlotinib or gefitinib - in previously-untreated patients with locally-advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Tagrisso met the primary endpoint of progression-free survival.
Progression-free survival results with Tagrisso were said to have been consistent across all pre-specified patient subgroups, including in patients with or without central nervous system metastases.
Overall survival data were not mature at the time of the final PFS analysis.
The FTSE 100 drugmaker said the approval was based on results from the Phase III FLAURA trial, which were presented at the European Society of Medical Oncology 2017 Congress and published in the New England Journal of Medicine.
"Today's FDA approval of Tagrisso in the first-line setting is an exciting milestone for patients and our company," said Dave Fredrickson, executive vice president, head of the oncology business unit at AstraZeneca.
"Tagrisso delivered unprecedented median progression-free survival data across all pre-specified patient subgroups, including patients with or without CNS metastases, and could prolong the lives of more patients without their tumours growing or spreading."
Dr Suresh S Ramalingam, the principal investigator of the FLAURA trial from the Winship Cancer Institute of Emory University in Atlanta, said the approval of osimertinib in the first-line setting represented a "major advance" in the treatment of patients with epidermal growth factor receptor mutations, and a "significant change" in the treatment paradigm.
"Osimertinib provides robust improvements in progression-free survival with no unexpected safety signals compared to the previous generation of EGFR inhibitors."
AstraZeneca said the FLAURA trial compared Tagrisso to current first-line tyrosine kinase inhibitors - erlotinib or gefitinib - in previously-untreated patients with locally-advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.
Tagrisso met the primary endpoint of progression-free survival.
Progression-free survival results with Tagrisso were said to have been consistent across all pre-specified patient subgroups, including in patients with or without central nervous system metastases.
Overall survival data were not mature at the time of the final PFS analysis.
Related share prices |
---|
AstraZeneca (AZN) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price